Detalhe da pesquisa
1.
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.
Diabetes Obes Metab
; 24(8): 1439-1447, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661378
2.
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Diabetes Care
; 44(4): 960-968, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33622669
3.
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
Sci Transl Med
; 11(475)2019 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30651321
4.
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.
Diabetes Technol Ther
; 5(3): 355-63, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12828817
5.
Beta 2-adrenergic receptor stimulated, G protein-coupled receptor kinase 2 mediated, phosphorylation of ribosomal protein P2.
Biochemistry
; 41(42): 12850-7, 2002 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-12379128